T1	Participants 422 505	multisite, two-part study of risperidone in children ages 5 to 17 years with autism
T2	Participants 660 705	4-month open-label treatment with risperidone
T3	Participants 1013 1024	63 children
T4	Participants 1385 1405	included 32 patients
T5	Participants 1663 1671	children
